Aditya Birla Sun Life Pharma & Healthcare Fund Datagrid
Category Pharma Fund
BMSMONEY Rank -
Rating
Growth Option 12-06-2026
NAV ₹33.64(R) +0.69% ₹37.37(D) +0.67%
Returns 1Y 3Y 5Y 7Y 10Y
Lumpsum Regular 10.62% 23.68% 12.4% -% -%
Direct 12.09% 25.34% 13.99% -% -%
Nifty Pharma TRI 11.55% 24.71% 11.87% 17.8% 9.34%
SIP (XIRR) Regular 15.75% 14.37% 16.25% -% -%
Direct 17.24% 15.92% 17.83% -% -%
Ratio Sharpe Ratio Sortino Ratio Sterling Ratio Jensen's Alpha Treynor Ratio
1.0 0.55 0.89 0.32% -0.41
Risk STD. Dev VaR 1Y95% Max DD Beta Semi Devi.
16.02% -16.54% -15.36% 0.92 11.07%
Fund AUM As on: 30/12/2025 846 Cr
Top Pharma Fund
Fund Name Rank Rating
Mirae Asset Healthcare Fund -
Aditya Birla Sun Life Pharma & Healthcare Fund -
Uti Healthcare Fund -
Sbi Healthcare Opportunities Fund -
Icici Prudential Pharma Healthcare And Diagnostics (P.H.D) Fund -
Nippon India Pharma Fund -
Tata India Pharma & Healthcare Fund -

NAV Date: 12-06-2026

Scheme Name NAV Rupee Change Percent Change
Aditya Birla Sun Life Pharma and Healthcare Fund-Regular - Payout of IDCW 22.21
0.1500
0.6800%
Aditya Birla Sun Life Pharma and Healthcare Fund-Direct - Payout of IDCW 24.3
0.1700
0.7000%
Aditya Birla Sun Life Pharma and Healthcare Fund-Regular-Growth 33.64
0.2300
0.6900%
Aditya Birla Sun Life Pharma and Healthcare Fund-Direct-Growth 37.37
0.2500
0.6700%

Review Date: 12-06-2026

Beginning of Analysis

The 3 star rating shows an average past performance of the Aditya Birla Sun Life Pharma & Healthcare Fund in Pharma Fund. The Aditya Birla Sun Life Pharma & Healthcare Fund has a Jensen Alpha of 0.32% which is lower than the category average of 0.91%, showing poor performance. The Aditya Birla Sun Life Pharma & Healthcare Fund has a Sharpe Ratio of 1.0 which is lower than the category average of 1.01, showing poor performance.
The past performance of the {fund_name_eng} may or may not be sustained in the future. The review is not investment advice nor is it a recommendation to buy or sell funds.
Pharma Mutual Funds

Aditya Birla Sun Life Pharma & Healthcare Fund Return Analysis

The Aditya Birla Sun Life Pharma & Healthcare Fund has delivered a mixed performance across various time horizons, showcasing both strengths and challenges when compared to its Pharma Fund peers and the Nifty Pharma TRI benchmark. This analysis examines the fund’s returns over periods ranging from one month to ten years, alongside its Systematic Investment Plan (SIP) performance, highlighting its rankings within the Pharma Fund category and its ability to outperform or underperform the benchmark and category averages.

  • The fund has given a return of 2.86%, 8.04 and 10.04 in last one, three and six months respectively. In the same period the category average return was 3.16%, 9.88% and 9.06% respectively.
  • Aditya Birla Sun Life Pharma & Healthcare Fund has given a return of 12.09% in last one year. In the same period the Nifty Pharma TRI return was 11.55%. The fund has given 0.54% more return than the benchmark return.
  • The fund has given a return of 25.34% in last three years and rank 5th out of eight funds in the category. In the same period the Nifty Pharma TRI return was 24.71%. The fund has given 0.63% more return than the benchmark return.
  • Aditya Birla Sun Life Pharma & Healthcare Fund has given a return of 13.99% in last five years and category average returns is 15.12% in same period. The fund ranked 7.0th out of eight funds in the category. In the same period the Nifty Pharma TRI return was 11.87%. The fund has given 2.12% more return than the benchmark return.
  • The fund has given a SIP return of 17.24% in last one year whereas category average SIP return is 17.26%. The fund one year return rank in the category is 9th in 15 funds
  • The fund has SIP return of 15.92% in last three years and ranks 5th in 8 funds. Uti Healthcare Fund has given the highest SIP return (18.47%) in the category in last three years.
  • The fund has SIP return of 17.83% in last five years whereas category average SIP return is 18.62%.

Aditya Birla Sun Life Pharma & Healthcare Fund Risk Analysis

  • The fund has a standard deviation of 16.02 and semi deviation of 11.07. The category average standard deviation is 15.97 and semi deviation is 11.32.
  • The fund has a Value at Risk (VaR) of -16.54 and a maximum drawdown of -15.36. The category average VaR is -19.09 and the maximum drawdown is -14.79. The fund has a beta of 0.92 which shows that fund is less volatile than the benchmark.

Standard deviation measures the fund's return volatility and Semi deviation focuses on downside volatility. Value at Risk (VaR) is a measure of the risk of investments. Maximum Drawdown is the maximum loss from a peak to a trough of a portfolio. Beta measures the volatility of the fund compared to the benchmark. A beta of 1 indicates that the fund will move in line with the benchmark. A beta of more than 1 indicates that the fund will be more volatile than the benchmark and vice versa.


  • Very Good Performance in Pharma Fund Category
  • Good Performance in Pharma Fund Category
  • Poor Performance in Pharma Fund Category
  • Very Poor Performance in Pharma Fund Category

    • Investors beware: Mutual Fund investments are subject to market risks. Please read the scheme related documents carefully.

    Data Source: www.amfiindia.com

    SEBI Categorization


    KPIs* Fund Nifty Pharma TRI Cat. Avg Min | Max Rank (In Cat.) Performance
    1M Return % 2.78 2.37
    3.04
    		1.32 | 5.61 10 | 16 Average
    3M Return % 7.68 4.86
    9.50
    		5.14 | 12.91 12 | 16 Average
    6M Return % 9.33 7.24
    8.33
    		3.22 | 13.97 7 | 16 Good
    1Y Return % 10.62 11.55
    9.75
    		4.62 | 18.10 7 | 15 Good
    3Y Return % 23.68 24.71
    24.26
    		22.21 | 26.76 5 | 8 Average
    5Y Return % 12.40 11.87
    13.75
    		12.39 | 15.51 7 | 8 Poor
    1Y SIP Return % 15.75
    15.74
    		7.07 | 24.98 9 | 15 Average
    3Y SIP Return % 14.37
    14.82
    		11.81 | 17.29 5 | 8 Average
    5Y SIP Return % 16.25
    17.23
    		15.29 | 19.63 6 | 8 Average
    Standard Deviation 16.02
    15.97
    		14.75 | 16.83 4 | 8 Good
    Semi Deviation 11.07
    11.32
    		10.52 | 12.07 3 | 8 Good
    Max Drawdown % -15.36
    -14.79
    		-16.36 | -12.33 6 | 8 Average
    VaR 1 Y % -16.54
    -19.09
    		-23.30 | -15.67 2 | 8 Very Good
    Average Drawdown % -6.79
    -5.48
    		-6.79 | -3.72 8 | 8 Poor
    Sharpe Ratio 1.00
    1.01
    		0.85 | 1.20 5 | 8 Average
    Sterling Ratio 0.89
    0.92
    		0.79 | 1.09 6 | 8 Average
    Sortino Ratio 0.55
    0.53
    		0.43 | 0.63 4 | 8 Good
    Jensen Alpha % 0.32
    0.91
    		-2.04 | 4.20 5 | 8 Average
    Treynor Ratio -0.41
    -0.43
    		-0.48 | -0.40 4 | 8 Good
    Modigliani Square Measure % 23.47
    23.67
    		20.89 | 27.07 5 | 8 Average
    Alpha % -1.30
    -1.43
    		-3.34 | 1.08 4 | 8 Good
    Return data last Updated On : June 12, 2026.
    Other parameters, fund ranking, non return related analysis are updated after every month end. Last Updated On : March 30, 2026
    KPIs: Key Performance Indicators

    Rotate the phone! Best viewed in landscape mode on mobile.
    KPIs* Fund Nifty Pharma TRI Cat. Avg Min | Max Rank (In Cat.) Performance
    1M Return % 2.86 2.37 3.16 1.37 | 5.73 10 | 16 Average
    3M Return % 8.04 4.86 9.88 5.37 | 13.28 12 | 16 Average
    6M Return % 10.04 7.24 9.06 3.95 | 14.89 7 | 16 Good
    1Y Return % 12.09 11.55 11.23 5.59 | 19.48 6 | 15 Good
    3Y Return % 25.34 24.71 25.72 23.31 | 27.82 5 | 8 Average
    5Y Return % 13.99 11.87 15.12 13.40 | 16.74 7 | 8 Poor
    1Y SIP Return % 17.24 17.26 8.59 | 26.46 9 | 15 Average
    3Y SIP Return % 15.92 16.19 13.27 | 18.47 5 | 8 Average
    5Y SIP Return % 17.83 18.62 16.51 | 20.89 6 | 8 Average
    Standard Deviation 16.02 15.97 14.75 | 16.83 4 | 8 Good
    Semi Deviation 11.07 11.32 10.52 | 12.07 3 | 8 Good
    Max Drawdown % -15.36 -14.79 -16.36 | -12.33 6 | 8 Average
    VaR 1 Y % -16.54 -19.09 -23.30 | -15.67 2 | 8 Very Good
    Average Drawdown % -6.79 -5.48 -6.79 | -3.72 8 | 8 Poor
    Sharpe Ratio 1.00 1.01 0.85 | 1.20 5 | 8 Average
    Sterling Ratio 0.89 0.92 0.79 | 1.09 6 | 8 Average
    Sortino Ratio 0.55 0.53 0.43 | 0.63 4 | 8 Good
    Jensen Alpha % 0.32 0.91 -2.04 | 4.20 5 | 8 Average
    Treynor Ratio -0.41 -0.43 -0.48 | -0.40 4 | 8 Good
    Modigliani Square Measure % 23.47 23.67 20.89 | 27.07 5 | 8 Average
    Alpha % -1.30 -1.43 -3.34 | 1.08 4 | 8 Good
    Return data last Updated On : June 12, 2026.
    Other parameters, fund ranking, non return related analysis are updated after every month end. Last Updated On : March 30, 2026
    KPIs: Key Performance Indicators

    Disclaimer: Past performance may or may not be sustained in future and should not be used as a basis for comparison with other investments. Returns for periods above 1 year are annualised.


    Date Aditya Birla Sun Life Pharma & Healthcare Fund NAV Regular Growth Aditya Birla Sun Life Pharma & Healthcare Fund NAV Direct Growth
    12-06-2026 33.64 37.37
    11-06-2026 33.41 37.12
    10-06-2026 33.4 37.11
    09-06-2026 33.56 37.28
    08-06-2026 33.24 36.93
    05-06-2026 33.21 36.89
    04-06-2026 33.0 36.65
    03-06-2026 32.92 36.57
    02-06-2026 32.75 36.38
    01-06-2026 32.82 36.45
    29-05-2026 33.04 36.7
    27-05-2026 33.47 37.17
    26-05-2026 33.46 37.16
    25-05-2026 33.65 37.37
    22-05-2026 33.51 37.21
    21-05-2026 33.78 37.51
    20-05-2026 33.68 37.39
    19-05-2026 33.68 37.39
    18-05-2026 33.56 37.26
    15-05-2026 33.56 37.25
    14-05-2026 33.49 37.17
    13-05-2026 32.79 36.4
    12-05-2026 32.73 36.33

    Fund Launch Date: 11/Jul/2019
    Fund Category: Pharma Fund
    Investment Objective: The scheme provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. The Scheme does not guarantee/ indicate any returns. There can be no assurance that the schemes’ objectives will be achieved.
    Fund Description: An open ended equity scheme investing in Pharma and Healthcare Services Sector
    Fund Benchmark: S&P BSE Healthcare Total Return Index
    Source: Fund FactSheet

    Disclaimer: NO INVESTMENT ADVICE. The Content is for informational purposes only.